What is Pharmacogenetics:
Individual patient response to medications is influenced by genetic variation in the enzymes responsible for drug metabolism as well as targeted receptors and transporters.
The majority of drugs enter the body and have to be metabolized before giving good therapy. Knowing what genetic variants are present or not, leads to more effective medication prescribing.
Alterations in enzyme function are categorized info four phenotypes. Knowing a patient’s metabolic phenotype and its impact on drug metabolism can empower clinical treatment decisions, increase drug efficacy and reduce the risk of adverse events.
- Extensive Metabolizers: (EM) carry 2 functional genes and have normal enzyme activity. Standard medication dosing is appropriate for extensive metabolizers.
- Poor Metabolizers (PM) have severely reduced or no functional capacity to metabolize substrate medications. Poor metabolizers are at risk for side effects due to toxic drug accumulation and may require lower doses.
- Intermediate Metabolizers (IM) also have a severely reduced capacity to metabolize drugs and therefore may also require modified drug doses.
- Ultra-Rapid Metabolizers (UM) typically carry multiple copies of the same gene and have elevated enzyme activity and may need increasing drug dosing or decreased drug dosing, in the case of pro-drugs, in order to offset the higher rate of metabolism.
Variations in metabolism can cause life-threatening toxicity in one person and reduce drug effectiveness in another.
The PGx Medical proprietary program provides clinicians with valuable patient-specific information to make better therapeutic treatment decisions to determine, right drug, at the right dose, for the right person.
To learn more about getting started with pharmacogenetics, call us at 405-509-5112 or email firstname.lastname@example.org